HRAS is a frequently mutated oncogene especially in head and neck cancer (3.9%), bladder cancer (5.1%), vulvar squamous cell carcinoma (9.3%), cutaneous squamous cell carcinoma and lung cancer (3.8%) [1–3]. The gene discussed is HRAS; the disease is urinary bladder carcinoma.